Basel, Switzerland & Lincolnshire, Illinois, August,11, 2026
Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on targeted therapies for rare vascular diseases, has announced the closing of an oversubscribed $152 million Series B financing and the initiation of the global Phase 3 HEROIC clinical study evaluating investigational engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT). The combined financing and clinical-development milestones mark Vaderis’ transition into pivotal-stage development for engasertib, an investigational once-daily oral allosteric AKT inhibitor. The company expects proceeds from the financing to support planned operations through regulatory submissions and potential U.S. regulatory approval of engasertib.
$152 Million Financing Supports Pivotal Development
The $152 million Series B financing was completed through a private placement with selected investors and was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX. Participants included Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia. According to Vaderis, the financing provides the company with the capital needed to advance engasertib through its planned clinical and regulatory activities and potentially toward a U.S. regulatory submission.
The financing comes as Vaderis moves its lead program into a pivotal-stage clinical development phase. The company said the investment reflects confidence in engasertib’s potential to address a significant unmet medical need in HHT, a rare genetic vascular disorder for which there are currently no approved therapies worldwide. The transaction also provides resources to support the global development program as Vaderis seeks to generate additional clinical evidence for the investigational treatment.
Global Phase 3 HEROIC Study Begins
Advertisement
Vaderis has initiated HEROIC, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of once-daily oral engasertib in patients with moderate-to-severe HHT. The study is expected to enroll participants at clinical sites across North America, South America and Europe, representing a major expansion of the development program following earlier proof-of-concept research.
The initiation of HEROIC follows the publication of positive proof-of-concept and long-term extension data for engasertib in The New England Journal of Medicine. According to Vaderis, those data demonstrated clinically meaningful and sustained improvements across multiple measures of HHT disease. The company considers these findings an important scientific foundation for advancing engasertib into pivotal development and evaluating its potential in a larger patient population.
Engasertib Targets Rare Vascular Disease
Engasertib (VAD044) is an investigational oral selective allosteric inhibitor of AKT1/2 being developed specifically for HHT. The disease is a rare genetic vascular disorder characterized by recurrent bleeding, severe nosebleeds, anemia and visceral arteriovenous malformations (AVMs). Vaderis estimates that HHT affects approximately one in 3,800 people. Despite the significant burden associated with the condition, there are currently no approved therapies specifically indicated for HHT globally.Engasertib is designed to target dysregulated signaling pathways associated with vascular malformations, with the goal of addressing the underlying pathophysiology of HHT rather than focusing solely on symptoms. The Phase 3 HEROIC study will provide an important test of whether the encouraging findings from earlier clinical research can be confirmed in a larger, controlled trial.
The development program represents a significant milestone for Vaderis and the broader rare-disease biopharmaceutical sector. If successful, engasertib could potentially become the first approved therapy specifically developed for people living with HHT. However, the company emphasizes that engasertib has not been approved for any indication in any country, and its safety and efficacy have not been established by regulatory authorities. The combination of a substantial Series B financing and initiation of a global Phase 3 study positions Vaderis for an important stage of clinical development. The HEROIC trial will now determine whether engasertib can deliver the efficacy and safety needed to support future regulatory submissions and potentially provide a new targeted treatment option for patients affected by this rare vascular disease.
Source: Vaderis Therapeutics press release
